We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia

By LabMedica International staff writers
Posted on 29 Oct 2026

Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More...

More than 120,000 people in the U.S. are living with ALL, with about 6,000 new cases diagnosed each year, including more than 3,500 in children.

Treatment often involves combinations of chemotherapy, targeted therapy, immunotherapy, and bone marrow transplantation, but determining how an individual patient will respond to specific drug combinations and doses remains difficult before therapy begins. To address this challenge, researchers have developed a lab-on-a-chip approach for testing pediatric ALL drug responses at diagnosis.

A team of scientists at Emory University, Children’s Healthcare of Atlanta, and Georgia Tech has developed GradientScreen, a microfluidic assay designed to measure how a patient’s leukemia cells respond to drug combinations using a single blood or bone marrow sample. The lab-on-a-chip exposes leukemia cells to three-drug combinations and measures how many cancer cells survive. Rather than testing each drug pair and dose ratio separately, the assay uses microfluidic technology to evaluate the full range of combination ratios within a three-drug regimen in a single experiment.

By comparing responses to individual drugs and drug combinations, GradientScreen identifies combinations and dose ratios that produce stronger effects together. These response patterns are intended to reflect how a patient’s leukemia may respond to treatment, complementing genomic and related data with direct measurements of drug sensitivity.

In a retrospective study, the platform was evaluated using 17 leukemia cell and bone marrow samples from patients with ALL. The samples were provided by the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. GradientScreen results correlated with patient treatment outcomes, including residual disease after induction therapy, the first month of chemotherapy, and whether the patient later relapsed.

The study was published in Nature Biomedical Engineering on October 23, 2026. The collaborators stated that the technology could help identify harder-to-treat patients earlier and more precisely match them with new or alternative treatment approaches. Next steps include expanding the platform to other leukemia types, including acute myeloid leukemia, and evaluating it in both adult and pediatric patients.

“One of the holy grails in oncology is the ability to identify which patient is likely to be unresponsive to standard treatment before initiation of therapy begins, and to personalize which combination of standard chemotherapies with newer targeted or biological agents would be most beneficial, and at which dosages, for that particular person,” said Wilbur Lam, M.D., Ph.D., professor of pediatrics and biomedical engineering at Emory University and Georgia Tech and principal investigator on the study.

"This is a significant advancement in helpng pediatric oncologists nationwide understand which drugs to administer to patients who are most likely to resist standard chemotherapy," added Lam.

Related Links
Emory University
Georgia Tech 
Children’s Healthcare of Atlanta 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The MIRAM GAGome Kit quantifies urine CS disaccharides by UHPLC-MS/MS, supporting exploratory and translational research across disease areas. (Photo courtesy of Elypta)

Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction

Cancer risk stratification in healthy adults often relies on established factors such as age and smoking history. However, several cancers highlighted in the study, including pancreatic, kidney, and brain... Read more

Molecular Diagnostics

view channel
Image: A blood test measuring circulating tumor DNA may help identify men with hormone-resistant oligoprogressive prostate cancer most likely to benefit from stereotactic body radiotherapy (Image Credit: Adobe Stock)

Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer

Advanced prostate cancer can progress despite hormone-based treatment, with imaging sometimes revealing only limited areas of active disease. For men with hormone-resistant oligoprogressive prostate cancer,... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.